Top Health Tools
Top Health Tools

Top Reports
Top Reports
Top Articles
Top Articles

Top Reviews
Top Reviews
Tamiflu Manufacturer Refuses To Disclose Evidence Suggesting Zero Effectiveness

Roche, the manufacturer of Tamiflu, has made it impossible for scientists to assess how well the anti-flu drug stockpiled around the globe works by withholding the evidence the company has gained from trials, doctors alleged.

Review published in British Medical Journal accuses flu drug manufacturer Roche of withholding evidence from trials

A major review of what data there is in the public domain has already found no evidence Tamiflu can prevent healthy people with flu from suffering complications such as pneumonia. Tamiflu has actually been found to cause pneumonia and respiratory failure.

Staunch critic of the drug, Dr. Jonathan Lackow stated "unpublished preliminary evidence suggested that Tamiflu had zero effectiveness and it's obvious why they don't want to make that evidence public."

The investigators say It is impossible to know whether it prevents severe disease because the published data is insufficient. Roche has failed to make some of the studies carried out on the drug publicly available, the scientists say.

A recent study conducted by the National Institute for Viral Disease Control and Chinese Center for Disease Control and Prevention has found that Tamiflu (oseltamivir) boosts H1N1 viral infection.

"Governments around the world have spent billions of pounds on a drug that the scientific community now finds itself unable to judge," said Dr Fiona Godlee, editor of the British Medical Journal, which published the new review online and collaborated in a joint investigation with Channel 4 News, shown this evening .

Roche has made a fortune out of the drug, with sales of £1.6bn this year alone. The British government has stockpiled enough for half the population.

In the review, Professor Chris Del Mar, from Bond University in Australia, analysed 20 published trials that focused on prevention, treatment and adverse reactions. The authors say they were hampered by the "paucity of good data".

The reviewers were forced to leave out eight trials because they had not been published, and Roche offered them "under conditions we thought unacceptable, and what was offered to us was insufficient to analyse properly."

Because they did not have full access to all the trials, the reviewers say previous evidence on the effects of Tamiflu and other drugs of this class (the neuraminidase inhibitors) may be unreliable. They call on governments to set up studies to monitor the drugs for safety.

A second review was carried out in the UK at Birmingham University by Professor Nick Freemantle and Dr Melanie Calvert, who analysed a series of observational studies Roche provided. (These are studies of people who took the drugs, but without a comparison group of people who did not take them.)

Freemantle said he saw "very little evidence to support the widespread use of oseltamivir in the otherwise healthy population who are developing signs of influenza-like illness."

He added: "We have remarkably few resources in this country to spend on pharmaceuticals on health, and it is surprising to see such widespread use of oseltamivir. But I suppose that once you've gone and bought lots of doses, then it's a bit like the situation with gun control in the US. If you have a gun in the house, it is much easier to use it. But it does not mean it's the right thing to do."

Dr Godlee and Professor Mike Clarke, director of the UK Cochrane Centre, call in the BMJ for new global legislation to ensure all trial data on drugs that have been granted a licence must be published in full.

Roche has now undertaken to put summaries of all the Tamiflu study data on a password-protected site.

Reference Source 147, 241
December 10, 2009

STAY CONNECTEDNewsletter | RSS | Twitter | YouTube |
This site is owned and operated by 1999-2018. All Rights Reserved. All content on this site may be copied, without permission, whether reproduced digitally or in print, provided copyright, reference and source information are intact and use is strictly for not-for-profit purposes. Please review our copyright policy for full details.
volunteerDonateWrite For Us
Stay Connected With Our Newsletter